Semi-Annual Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7723173

Concept As at
2018-06-30
2018-01-01 to
2018-06-30
As at
2017-12-31
2017-01-01 to
2017-06-30
As at
2017-06-30
As at
2016-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-639,994,000 JPY
-517,038,000 JPY
Depreciation
737,000 JPY
401,000 JPY
Interest and dividend income
-9,120,000 JPY
-1,973,000 JPY
Interest expenses
1,480,000 JPY
1,596,000 JPY
Foreign exchange losses (gains)
8,972,000 JPY
7,478,000 JPY
Decrease (increase) in trade receivables
36,445,000 JPY
61,872,000 JPY
Decrease (increase) in inventories
1,857,000 JPY
2,619,000 JPY
Other, net
16,591,000 JPY
-3,054,000 JPY
Subtotal
-611,836,000 JPY
-515,048,000 JPY
Interest and dividends received
142,000 JPY
427,000 JPY
Interest paid
-1,502,000 JPY
-1,653,000 JPY
Income taxes paid
-3,703,000 JPY
-3,186,000 JPY
Net cash provided by (used in) operating activities
-616,900,000 JPY
-519,460,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-1,129,000 JPY
-965,000 JPY
Purchase of investment securities
-356,310,000 JPY
-55,670,000 JPY
Net cash provided by (used in) investing activities
242,560,000 JPY
343,218,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
100,000,000 JPY
Repayments of long-term borrowings
-16,668,000 JPY
-11,536,000 JPY
Proceeds from issuance of shares
JPY
955,637,000 JPY
Net cash provided by (used in) financing activities
-32,071,000 JPY
1,042,018,000 JPY
Effect of exchange rate change on cash and cash equivalents
-8,938,000 JPY
-7,478,000 JPY
Net increase (decrease) in cash and cash equivalents
-415,350,000 JPY
858,298,000 JPY
Cash and cash equivalents
1,507,104,000 JPY
1,922,454,000 JPY
2,277,291,000 JPY
1,418,993,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.